[
    [
        {
            "time": "2018-03-15",
            "original_text": "Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies",
            "features": {
                "keywords": [
                    "Merck",
                    "Pneumococcal",
                    "Vaccine",
                    "Goal",
                    "Adult",
                    "Studies"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Pfizer Begins Four Phase III Studies on Vaccine Candidates",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Phase",
                    "III",
                    "Studies",
                    "Vaccine",
                    "Candidates"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pfizer Begins Four Phase III Studies on Vaccine Candidates",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-06-20",
            "original_text": "What's in Store for Patterson Companies' (PDCO) Q4 Earnings?",
            "features": {
                "keywords": [
                    "Patterson",
                    "Companies",
                    "Q4",
                    "Earnings"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "retail",
                    "medical supplies"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What's in Store for Patterson Companies' (PDCO) Q4 Earnings?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "Innoviva (INVA) Looks Good: Stock Adds 8.9% in Session",
            "features": {
                "keywords": [
                    "Innoviva",
                    "Stock",
                    "Adds",
                    "8.9%",
                    "Session"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Innoviva (INVA) Looks Good: Stock Adds 8.9% in Session",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]